Tags

Type your tag names separated by a space and hit enter

Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma. Kanazawa Asthma Research Group.
Pulm Pharmacol. 1995 Dec; 8(6):251-7.PP

Abstract

It has been considered that thromboxane A2 (TXA2) is involved in the development of bronchial hyperresponsiveness (BHR), a characteristic feature of asthma. To ensure the involvement of TXA2 in BHR of asthma, effects of a 1-week treatment with two orally active TXA2 antagonists, BAY u 3405 and S-1452, on BHR were examined in 10 and 13 patients with stable asthma, respectively, in two consecutive double-blinded, randomized, placebo-controlled, two-phase crossover studies. Provocative concentration of methacholine causing a 20% fall in FEV1 (PC20-FEV1) with BAY u 3405 (0.78 (GSEM, 1.50) mg/ml) was significantly greater than the value with placebo (0.65 (GSEM, 1.46) mg/ml) (ratio 1.23 times, 95% CI 1.01 to 1.46: P = 0.0401). PC20-FEV1 was also significantly increased with S-1452 (0.43 (GSEM, 1.39) mg/ml) compared with placebo (0.29 (GSEM, 1.27) mg/ml) (ratio 1.75 times, 95% CI 1.05 to 2.45: P = 0.0189). Baseline pulmonary function was not altered by these treatments. These results may ensure that TXA2 is significantly involved in the BHR of asthma while the degree of contribution may be small.

Authors+Show Affiliations

Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8819179

Citation

Fujimura, M, et al. "Involvement of Thromboxane A2 in Bronchial Hyperresponsiveness of Asthma. Kanazawa Asthma Research Group." Pulmonary Pharmacology, vol. 8, no. 6, 1995, pp. 251-7.
Fujimura M, Nakatsumi Y, Nishi K, et al. Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma. Kanazawa Asthma Research Group. Pulm Pharmacol. 1995;8(6):251-7.
Fujimura, M., Nakatsumi, Y., Nishi, K., Kasahara, K., & Matsuda, T. (1995). Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma. Kanazawa Asthma Research Group. Pulmonary Pharmacology, 8(6), 251-7.
Fujimura M, et al. Involvement of Thromboxane A2 in Bronchial Hyperresponsiveness of Asthma. Kanazawa Asthma Research Group. Pulm Pharmacol. 1995;8(6):251-7. PubMed PMID: 8819179.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma. Kanazawa Asthma Research Group. AU - Fujimura,M, AU - Nakatsumi,Y, AU - Nishi,K, AU - Kasahara,K, AU - Matsuda,T, PY - 1995/12/1/pubmed PY - 1995/12/1/medline PY - 1995/12/1/entrez SP - 251 EP - 7 JF - Pulmonary pharmacology JO - Pulm Pharmacol VL - 8 IS - 6 N2 - It has been considered that thromboxane A2 (TXA2) is involved in the development of bronchial hyperresponsiveness (BHR), a characteristic feature of asthma. To ensure the involvement of TXA2 in BHR of asthma, effects of a 1-week treatment with two orally active TXA2 antagonists, BAY u 3405 and S-1452, on BHR were examined in 10 and 13 patients with stable asthma, respectively, in two consecutive double-blinded, randomized, placebo-controlled, two-phase crossover studies. Provocative concentration of methacholine causing a 20% fall in FEV1 (PC20-FEV1) with BAY u 3405 (0.78 (GSEM, 1.50) mg/ml) was significantly greater than the value with placebo (0.65 (GSEM, 1.46) mg/ml) (ratio 1.23 times, 95% CI 1.01 to 1.46: P = 0.0401). PC20-FEV1 was also significantly increased with S-1452 (0.43 (GSEM, 1.39) mg/ml) compared with placebo (0.29 (GSEM, 1.27) mg/ml) (ratio 1.75 times, 95% CI 1.05 to 2.45: P = 0.0189). Baseline pulmonary function was not altered by these treatments. These results may ensure that TXA2 is significantly involved in the BHR of asthma while the degree of contribution may be small. SN - 0952-0600 UR - https://www.unboundmedicine.com/medline/citation/8819179/Involvement_of_thromboxane_A2_in_bronchial_hyperresponsiveness_of_asthma__Kanazawa_Asthma_Research_Group_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0952-0600(85)71034-4 DB - PRIME DP - Unbound Medicine ER -